Literature DB >> 24499222

Ponatinib in Philadelphia chromosome-positive leukemias.

Alfonso Quintas-Cardama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24499222     DOI： 10.1056/NEJMc1315234

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Ponatinib given for advanced leukemia relapse after allo-SCT.

Authors:  K Hirschbuehl; A Rank; T Pfeiffer; H R Slawik; G Schlimok; H J Kolb; Ch Schmid
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

2.  Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.

Authors:  Sara Robinson; Yair Levy; Christopher Maisel; Alex W Tong
Journal:  BMJ Case Rep       Date:  2014-04-12

3.  Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.

Authors:  Prajwal Boddu; Abdul Rashid Shah; Gautam Borthakur; Srdan Verstovsek; Guillermo Garcia-Manero; Naval Daver; Tapan Kadia; Farhad Ravandi; Nitin Jain; Ahmad Alhuraiji; Jan Burger; Steven Kornblau; Sherry Pierce; Sara Dellasala; Elias Jabbour; Hagop Kantarjian; Jorge Cortes
Journal:  Leuk Lymphoma       Date:  2017-10-03

Review 4.  Resistant mutations in CML and Ph(+)ALL - role of ponatinib.

Authors:  Geoffrey D Miller; Benjamin J Bruno; Carol S Lim
Journal:  Biologics       Date:  2014-10-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.